Tirzepatide (Mounjaro) for type 2 diabetes starts at 2.5 mg once weekly for four weeks, then increases to 5 mg
Comparative effectiveness of GLP-1 receptor agonists
the posts analyzed were dated between May 2019 and June 2025
Its effects on heart health are still being studied, but research suggests that it might improve heart rate and blood pressure
Lifestyle modifications complement pharmaceutical management
Safe alternatives include metformin, SGLT2 inhibitors (empagliflozin, dapagliflozin), DPP-4 inhibitors (sitagliptin, linagliptin), and exenatide immediate-release or lixisenatide, which do not carry thyroid cancer warnings